However, when tested in COPD studies, anti-cytokine treatments (tumour necrosis factor-α inhibitors, anti–IL-8 therapies, the anti–IL-1β antibody canakinumab) have had little clinical efficacy, despite showing potential in pre-clinical models [4, 36–42]. This evidence concerns the gene IL1B and chronic obstructive pulmonary disease.